1. Medtech Insight
  2. >>Policy & Regulation

Quibim Extends Into US Market With FDA Authorization Of QP-Prostate CAD

AI Radiology Tool For Prostate Cancer Lesion Detection

 
• By Natasha Barrow

The US FDA's clearance of QP-Prostate CAD positions the company to support US health care providers and growing markets for fusion biopsy and focal therapy, said Quibim CEO and founder Angel Alberich-Bayarri.

prostate cancer imaging
(Shutterstock)

Quibim, a health tech startup designing AI tools to unlock clinical imaging data, received US Food and Drug Administration authorization for its QP-Prostate computer-aided detection (CAD) solution for the detection of prostate cancer lesions on MRI scans on 19 March.

“Integrating AI technology into prostate MRI enhances diagnostic precision in identifying clinically significant prostate cancer,” said Angel Alberich-Bayarri, CEO and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Startups & SMEs